Your browser is no longer supported. Please, upgrade your browser.
Settings
NTGN Neon Therapeutics, Inc. daily Stock Chart
NTGN [NASD]
Neon Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.05 Insider Own4.90% Shs Outstand27.78M Perf Week7.75%
Market Cap42.50M Forward P/E- EPS next Y-1.44 Insider Trans-4.58% Shs Float23.02M Perf Month-15.93%
Income-85.10M PEG- EPS next Q-0.63 Inst Own55.90% Short Float2.78% Perf Quarter2.68%
Sales- P/S- EPS this Y-43.20% Inst Trans-4.42% Short Ratio1.64 Perf Half Y-44.77%
Book/sh1.62 P/B0.94 EPS next Y43.80% ROA-95.30% Target Price9.24 Perf Year-68.13%
Cash/sh1.59 P/C0.96 EPS next 5Y26.90% ROE-117.00% 52W Range0.88 - 7.51 Perf YTD29.66%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.63% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low73.86% ATR0.12
Employees102 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)56.46 Volatility4.99% 7.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.60% Profit Margin- Rel Volume0.23 Prev Close1.50
ShortableYes LT Debt/Eq0.00 EarningsMar 09 BMO Payout- Avg Volume390.75K Price1.53
Recom2.70 SMA202.20% SMA5013.23% SMA200-43.25% Volume89,350 Change2.00%
Nov-27-19Downgrade H.C. Wainwright Buy → Neutral
Nov-13-19Downgrade BofA/Merrill Buy → Neutral
Jul-26-19Initiated Robert W. Baird Outperform $15
Jun-04-19Initiated Mizuho Buy
May-30-19Initiated H.C. Wainwright Buy
Mar-27-19Initiated Berenberg Buy $15
Oct-01-18Initiated Ladenburg Thalmann Buy $20
Feb-24-20 07:00AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders TIVO, HXL, NTGN, FSB GlobeNewswire
Feb-20-20 08:00PM  LM, TIVO, NTGN, and DLPH SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers GlobeNewswire
Feb-19-20 06:40PM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders NTGN, FSB, CSFL, DLPH GlobeNewswire
Feb-16-20 09:46AM  SHAREHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Transaction ACCESSWIRE
Feb-13-20 09:45AM  URGENT NEWS: Monteverde & Associates PC is Investigating the Following Merger ACCESSWIRE
Feb-12-20 01:35PM  SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - LOGM, CBB, NTGN ACCESSWIRE
Feb-11-20 09:00PM  NTGN, FSB, GDI, and TLRA SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers GlobeNewswire -5.88%
04:14AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders LOGM, CBB, NTGN, FSB GlobeNewswire
Feb-07-20 08:00PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation on the Following Merger PR Newswire -5.03%
Feb-05-20 01:35PM  INVESTOR ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - NTGN, OPB, GILT ACCESSWIRE
Feb-04-20 08:00PM  NTGN, FSB, TLRA, and CBB SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers GlobeNewswire +6.25%
Jan-29-20 12:25PM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - NTGN, FSB, CSFL ACCESSWIRE -5.96%
Jan-28-20 06:01PM  NEON THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neon Therapeutics, Inc. - NTGN Business Wire
Jan-24-20 01:50PM  Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Neon Therapeutics, Central Federal Bancshares, Franklin Financial Network, and Changyou.com Limited on behalf of Stockholders and Encourages Investors to Contact the Firm PR Newswire -5.68%
Jan-23-20 09:56AM  Moore Kuehn, PLLC Encourages NTGN, HXL, FSB, and WMGI Investors to Contact Firm PR Newswire
Jan-22-20 09:45AM  Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon Zacks
Jan-21-20 10:30AM  NEON THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger ACCESSWIRE
Jan-20-20 06:45PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Neon Therapeutics, Inc. - (NasdaqGS: NTGN) ACCESSWIRE
10:35AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Neon Therapeutics, Inc. to BioNTech SE is Fair to Shareholders ACCESSWIRE
09:00AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders TECD, AMTD, WMGI, NTGN GlobeNewswire
Jan-16-20 11:19AM  German biotech snaps up struggling Third Rock-founded drugmaker American City Business Journals +38.21%
07:30AM  BioNTech to acquire Neon to strengthen global leadership position in T cell therapies GlobeNewswire
Dec-20-19 05:47PM  Is Neon Therapeutics, Inc. (NTGN) Going To Burn These Hedge Funds ? Insider Monkey
Dec-18-19 08:01AM  Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01 GlobeNewswire
Nov-22-19 08:18AM  The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga
Nov-21-19 07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-20-19 04:54PM  Shares of Neon Therapeutics rise on restructuring plans MarketWatch
04:05PM  Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs GlobeNewswire
Nov-12-19 07:00AM  Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire -8.74%
Nov-08-19 07:00AM  Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Oct-09-19 08:00AM  Can Neon Therapeutics (NASDAQ:NTGN) Afford To Invest In Growth? Simply Wall St. +6.71%
Sep-06-19 07:27AM  The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication Benzinga +14.43%
Sep-05-19 04:01PM  Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens GlobeNewswire +14.12%
Aug-06-19 07:00AM  Neon Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire
Jul-15-19 09:32AM  Neon Therapeutics Shares Higher After Positive Cancer Vaccine Study Benzinga +6.94%
06:00AM  Neon Therapeutics Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers GlobeNewswire
Jul-11-19 10:08AM  Can We See Significant Institutional Ownership On The Neon Therapeutics, Inc. (NASDAQ:NTGN) Share Register? Simply Wall St.
Jun-03-19 08:00AM  Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference GlobeNewswire
May-13-19 08:00AM  Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update GlobeNewswire -6.08%
May-10-19 09:55AM  3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates Zacks
07:59AM  Alibaba (BABA) Gears Up for Q4 Earnings: What's in Store? Zacks
May-08-19 08:00AM  Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference GlobeNewswire
May-07-19 10:38AM  Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings? Zacks -5.48%
10:27AM  What's in Store for Booking Holdings' (BKNG) Q1 Earnings? Zacks
May-06-19 11:17AM  What's in the Offing for TripAdvisor's (TRIP) Q1 Earnings? Zacks
05:07AM  Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings? Zacks
Apr-08-19 07:00AM  Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer GlobeNewswire +6.56%
Mar-31-19 03:00PM  Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting GlobeNewswire
Mar-11-19 07:00AM  Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-04-19 08:00AM  Neon Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-27-19 07:25PM  Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting GlobeNewswire
Feb-21-19 08:00AM  Neon Therapeutics to Present at 8th Annual Leerink Partners Global Healthcare Conference GlobeNewswire
Feb-06-19 02:20PM  These 4 Biotech Stocks Are Leading The Industry ACCESSWIRE +19.34%
Jan-04-19 01:38PM  Can We See Significant Institutional Ownership On The Neon Therapeutics, Inc. (NASDAQ:NTGN) Share Register? Simply Wall St.
Jan-03-19 07:00AM  Neon Therapeutics Provides Business Update and Outlook for 2019 GlobeNewswire
Dec-06-18 07:00AM  Neon Therapeutics and Apexigen Announce First Patient Dosed in Neons NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma GlobeNewswire
Nov-16-18 08:00AM  Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe GlobeNewswire
Nov-12-18 04:15PM  Neon Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire -8.01%
Nov-09-18 08:00AM  Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancers 33rd Annual Meeting GlobeNewswire -9.07%
Nov-07-18 04:48PM  Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors GlobeNewswire +7.23%
Nov-01-18 04:15PM  Neon Therapeutics to Host Investor Event at Society for Immunotherapy of Cancer 33rd Annual Meeting GlobeNewswire +6.66%
Oct-22-18 06:00AM  Neon Therapeutics Presents Data from Ongoing Phase 1b NT-001 Clinical Trial at European Society for Medical Oncology 2018 Congress GlobeNewswire -14.25%
Oct-19-18 08:28AM  The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut Benzinga +6.38%
Oct-18-18 04:20PM  Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine GlobeNewswire
04:15PM  Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine PR Newswire
Oct-03-18 07:00AM  Neon Therapeutics to Present Data from Ongoing Phase 1b NT-001 Clinical Trial at the European Society for Medical Oncology 2018 Congress GlobeNewswire
Oct-01-18 05:22PM  Neon Therapeutics to Present at the Society for Immunotherapy of Cancer 33rd Annual Meeting GlobeNewswire +35.25%
09:47AM  Neon Therapeutics Congratulates Founder James P. Allison, Ph.D., for 2018 Nobel Prize in Physiology or Medicine GlobeNewswire
Sep-25-18 04:15PM  Neon Therapeutics to Present at Upcoming Investor Conferences in October GlobeNewswire +6.34%
Sep-06-18 04:15PM  Neon Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire
Aug-21-18 04:15PM  Neon Therapeutics Appoints Jolie M. Siegel as General Counsel GlobeNewswire
Aug-06-18 04:15PM  Neon Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire +8.47%
Jul-23-18 02:42PM  Morgan Stanley: Newly Public Neon Therapeutics Has Outperformance Potential Benzinga +8.50%
Jul-03-18 06:23AM  Goodwin dominates this years record batch of Mass. biotech IPOs American City Business Journals
Jul-02-18 07:30AM  [$$] Biotech Companies Continue IPO Hot Streak, But For How Long? The Wall Street Journal -7.06%
Jun-29-18 04:15PM  Neon Therapeutics Announces Closing of Initial Public Offering GlobeNewswire -6.53%
Jun-26-18 06:56PM  Neon Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GAYNOR RICHARDPresident of R&DNov 27Sale1.2422,32227,644156,500Nov 27 05:01 PM
GAYNOR RICHARDPresident of R&DNov 26Sale1.3123,00030,231178,822Nov 27 05:01 PM
GAYNOR RICHARDPresident of R&DNov 25Sale1.3720,00027,498201,822Nov 27 05:01 PM